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Major  advances  have  been  made  in  identifying  potential  vaccine  molecules  for  the  con-
trol  of  fasciolosis  in livestock  but  we  have  yet  to  reach  the  level  of  efﬁcacy  required  for
commercialisation.  The  pathogenesis  of  fasciolosis  is associated  with  liver  damage  that  is
inﬂicted by  migrating  and  feeding  immature  ﬂukes  as  well  as  host  inﬂammatory  immune
responses  to parasite-secreted  molecules  and  tissue  damage  alarm  signals.  Immune  sup-
pression/modulation  by the  parasites  prevents  the development  of  protective  immune
responses  as  evidenced  by the  lack of immunity  observed  in  naturally  and  experimentally
infected  animals.  In  our  opinion,  future  efforts  need  to  focus  on  understanding  how  para-
sites invade  and penetrate  the  tissues  of their  hosts  and  how  they  potentiate  and  control
the  ensuing  immune  responses,  particularly  in the  ﬁrst  days  of  infection.  Emerging  ‘omics’
data employed  in an  unbiased  approach  are  helping  us understand  liver  ﬂuke  biology  and,
in parallel  with  new  immunological  data,  to identify  molecules  that  are  essential  to  parasite
development  and  accessible  to vaccine-induced  immune  responses.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB
. Introduction
According to the United Nations, the world population
ill increase to 9 billion by 2050. The demand for animal-
erived food, which has been growing at a rate of >7% over
he last two decades, will correspondingly increase, both
n developed and developing countries (FABRE Technol-
gy Platform working group). Therefore, going forward, to
upport this population growth, we need to secure a sus-
ainable means of producing the quantity of food required,
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and we  need to do this in a safe and ethical manner to pro-
tect the consumer, the health and welfare of animals and
our environment (Foresight, 2011).
This global population growth will open up attractive
market prospects for countries with the capacity and tech-
nology to produce large quantities of high-quality animal
products (particularly beef, dairy, pig and sheep). The value
of farm-level animal production to the EU is over D 130 bil-
lion; farmers represent >8% of the workforce, and farms
employ >15 million people (FABRE Technology Platform
working group, 2025). As farming intensiﬁes, however,
issues surrounding disease control, the prevention of dis-
ease transmission from animals to humans (zoonosis), the
health and welfare of animals and the quality/safety of
s an open access article under the CC BY-NC-ND license
rinary P102 V. Molina-Hernández et al. / Vete
the food we consume will come to the forefront (FABRE
Technology Platform working group; Meat & Livestock
Australia: http://www.mla.com.au).
Ireland is a good example of a small European coun-
try whose economy depends heavily on agriculture and at
the same time has the ability to take advantage of these
future trends. Irish agriculture is primarily a grass-based
industry; of the total land area of 6.9 million hectares, 4.2
million (64%) is devoted to agriculture, 90% of which is pas-
ture. There are about 6.5 million cattle in Ireland and the
Irish sheep ﬂock exceeds 4.8 million head, with a breed-
ing ﬂock of 2.51 million head. During 2011, 548,000 tonnes
of beef and 37,000 tonnes of sheep meat were produced,
most of which was exported. Each year, 17,000 dairy farms
produce 5.4 billion litres of milk (Teagasc). These ﬁgures
provide a snapshot of how important the livestock indus-
try, altogether valued at D 5–6 billion per annum, can be
to a small economy such as Ireland’s with a population of
under 5 million (Bloemhoff et al., 2014).
2. Parasitic diseases impact hugely on the animal
production industry
Helminth parasites cause >55% of all farm animal dis-
eases in Europe and effective control strategies would
have a major impact on the sustainability of the live-
stock industry (Nieuwhof and Bishop, 2005; Murphy et al.,
2006; Morgan et al., 2013). In Europe, parasitic diseases
of farm animals are caused principally by infections with
the liver ﬂuke Fasciola hepatica, the lungworm Dictyocaulus
viviparus, and the gastrointestinal nematode parasites of
sheep (Haemonchus contortus, Teladorsagia circumcincta)
and cattle (Ostertagia ostertagi, Cooperia oncophora). These
parasites impact on livestock productivity by affecting
growth rates, fertility and the quality of wool and milk
production. In particular, during seasons of major ﬂuke
outbreaks, infection can result in many animal fatalities
(Piedraﬁta et al., 2010). In general, about 17% of animal
production is estimated to be lost through infection of
livestock with pathogens including these parasites (FABRE
Technology Platform working group).
The losses to the livestock industry as a result of par-
asitic helminths are compounded by the signiﬁcant effort
and cost of trying to control these infections with regu-
lar chemical treatments. Within Europe, the annual spend
on anthelmintic drugs for parasitic helminths of rumi-
nants has been estimated to be D 400 million (Selzer, 2009;
Morgan et al., 2013). These costs contribute to the overall
economic losses related to disease, which for F. hepatica,
in particular, are estimated to be US $3 billion globally
(Spithill et al., 1999a; Mas-Coma et al., 2005; Piedraﬁta
et al., 2010). However, anthelmintic resistance, especially
in gastrointestinal nematode parasites (Kotze et al., 2014),
has spread to the point that it is now a global concern and is
already impacting signiﬁcantly on livestock productivity in
many regions. Resistance is also becoming a serious issue
in liver ﬂuke (Fairweather, 2011; Dalton et al., 2013). The
use of chemical products to control parasitic infections is,
therefore, not sustainable in the long term because of the
likelihood of continual emergence of drug-resistant para-
site populations. Additionally, there are growing consumerarasitology 208 (2015) 101–111
concerns about chemical residues in food, and also the
detrimental impact they have on the environment (Dalton
and Mulcahy, 2001; Cooper et al., 2012). In particular, an
assessment report adopted by the Committee for Medic-
inal Products for Veterinary Use (European Commission)
has recently established maximum residue limits for tri-
clabendazole (TCBZ) in bovine and ovine milk, in addition
to those already set for ruminant muscle, fat, liver and
kidney (EMA, 2012). Recent ﬂukicide licensing restrictions
for lactating dairy cows only allow the use of albenda-
zole (ABZ) and oxyclosanide (OCZ) for ﬂuke control (HRPA,
2013). Unlike TCBZ which is active against both immature
and adult parasites, ABZ and OCZ have restrictive activity
against the adult parasites and use of these anthelmintics
often requires repeated treatments, which are not always
carried out in the ﬁeld (Fairweather and Boray, 1999; Power
et al., 2013).
Vaccines, on the other hand, are considered safe and are
acceptable to both users and consumers. New vaccine tech-
nologies and adjuvant development are further improving
food safety by ensuring that these leave no residues in
food (Parker et al., 2009; Adams et al., 2009). As no chem-
ical residues are passed onto pasture, vaccines are also
considered environmentally friendly. However, despite the
huge successes we  have made in vaccine development
against viruses and bacteria over the past 200 years (and
in recombinant vaccines in the last 30 years), with the
exception of the live attenuated Huskvac vaccine for lung-
worm,  there are no commercially viable vaccines for animal
(or human) helminth parasitic pathogens. More recently,
a new vaccine for H. contortus, Barbervax, consisting of
native gut-derived antigen complex has been launched in
Australia (www.barbervax.com.au).
3. Liver ﬂuke disease: a food-borne zoonotic disease
Liver ﬂuke disease, or fasciolosis, in sheep and cat-
tle results from infection with the trematode, F. hepatica
(Andrews, 1999). Due to the emergence of parasites resis-
tant to the frontline drug triclabendazole (TCBZ) and also
to climate changes favourable to the survival of the inter-
mediate host (Galba truncatula)  and the infective stage
(metacercariae) of the parasite (Piedraﬁta et al., 2010), con-
sistently high prevalence levels of liver ﬂuke have been
recorded across Europe (recently reviewed by Charlier
et al., 2014). Within the UK, the prevalence of fasciolosis has
shown a marked increase, speciﬁcally in dairy herds from
48 to 72% from 2003 to 2006 (McCann et al., 2010) and,
more markedly, the distribution of liver ﬂuke has spread to
include areas of Scotland and East Anglia (Pritchard et al.,
2005; Kenyon et al., 2009). The increased prevalence of
F. hepatica further adds to the economic impact of this
parasite and indicates that the potential losses are greatly
under-represented.
F. hepatica is also an important pathogen of humans
in certain regions of the world where farm management
practices allow infected animals to roam amongst vege-
tation consumed by humans. Global human infections are
estimated to be between 2 and 17 million with 180 mil-
lion people at risk; prevalence is particularly high in the
Andean Altiplano (Bolivia, Peru and Ecuador) with lower
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nfection numbers recorded in Egypt, Iran and South East
sia (Mas-Coma, 2005; Mas-Coma et al., 2009; Gonzalez
t al., 2011). The widening geographical distribution of liver
uke also has an impact on human infections, with fasci-
losis recently being reported in areas of Pakistan (Afshan
t al., 2014). Besides better farm management procedures,
ontrol of human infections would greatly beneﬁt from a
accine targeting animal infections.
The discovery of novel means of control and interven-
ion for fasciolosis requires us to be cogniscent of each
tage of the parasite’s life cycle and interpret this as a com-
lex interplay between parasite and host. Parasite stages
ermed cercariae are released by snails that encyst on grass
nd other vegetation as metacercariae, which can survive
or up to a year (Andrews, 1999). Following ingestion by
razing animals, the parasites emerge from their cysts in
he intestine (we term these newly excysted juveniles,
EJ), traverse the intestinal wall, which takes just a few
ours, before migrating through the liver capsule and into
he parenchyma. Here their feeding and migratory activ-
ties cause tissue perforation and haemorrhage, leading
o extensive tissue damage. After about 7–8 weeks, the
arasites migrate into the bile ducts, mature and produce
0,000–24,000 eggs per ﬂuke per day which are released
nto the pasture with the faeces (Boray, 1969). Following
mbryonation on pasture, the eggs hatch and release motile
iracidia that infect mud  snails and initiate another cycle
f infection.
The liver damage caused by these migrating parasites
educes animal performance, fertility and wool and milk
roduction (reviewed by Sangster, 2001; Mezo et al., 2008;
nubben-Schweizer et al., 2010; Animal Health Ireland,
011; Charlier et al., 2014). These injurious pathogenic
ffects are compounded by the negative impact the parasite
as on the immune system; potent immunosuppressive
olecules secreted by the parasite compromise the natural
esistance of the host and promote co-infections resulting
n microbial diseases such as salmonellosis, clostridiosis
nd tuberculosis (Aitken et al., 1979, 1981; Hall et al., 1981;
rady et al., 1999; Flynn et al., 2007, 2009; Dalton et al.,
013). The parasites can live for very long periods (longest
ecorded 11 years in sheep; Durbin, 1952) inﬂicting long-
erm damage, causing low performance (Piedraﬁta et al.,
010) and possibly reduced ability to resist other infections.
. F. hepatica-induced tissue damage and the
mmune response: partners in hepatic pathology
The early pathogenesis of fasciolosis involves two
tages. A pre-hepatic stage is caused by the penetration of
EJ through the host intestine wall and migration within
he peritoneal cavity, which lasts for approximately 3 days
fter the primary infection (Kendall and Parﬁtt, 1962). Ani-
als display no clinical signs at this time and pathological
ndings are rare, except for small haemorrhagic foci in the
eritoneum layer. No changes are observed in the intestine
all (Kendall and Parﬁtt, 1962; Boray, 1969; Kelly, 1993;
afra et al., 2013a, 2013b), which suggests that the parasite
oves swiftly through this tissue and/or possesses a mech-
nism that suppresses immune activation within the tissue.
owever, the parasites clearly induce an ‘immunologicalarasitology 208 (2015) 101–111 103
presence’ as the cellular component of the peritoneal ﬂuid
does change, with the inﬁltration of a large number of
immune cells such as lymphocytes, macrophages and,
especially, eosinophils (Zafra et al., 2013a, 2013b). Control
of the host immune system by F. hepatica likely begins here
as experiments in laboratory animals have demonstrated
that recruitment and activation of M2  macrophages is
evident within 24 h after infection (Donnelly et al., 2005,
2008; Adams et al., 2014) and that ﬂukes induce an apop-
totic effect on peritoneal immune cells (Serradell et al.,
2007; Guasconi et al., 2012). This early immunomodulatory
effect likely plays a critical role in determining the ultimate
outcome of F. hepatica infection and is triggered directly by
molecules (such as proteases, protease inhibitors and anti-
oxidants) secreted from the parasite and by host molecules
(alarmins) that signal tissue damage to stimulate immune
repair mechanisms (Dalton et al., 2013).
Between 4 and 6 days post-infection, the majority of
NEJ have penetrated the liver capsule and established
themselves ﬁrmly within the parenchymal tissue, which
initiates the hepatic stage of pathogenesis. Depending on
the deﬁnitive host, the time of migration from intestine
to liver can extend up to 10 days (Dawes and Hughes,
1964; Sukhdeo and Sukhdeo, 2002). Here, the parasites
move randomly, forming characteristic transects/tunnels
and feed on the hepatic cellular components and blood
for 5–6 weeks (parenchymal phase), before reaching the
bile duct where they develop into their adult form (bil-
iary phase) at 7–8 weeks post-infection (Sinclair, 1967;
Dow et al., 1967; Rushton and Murray, 1977). As a result of
their parenchymal feeding activity, NEJ grow and develop
rapidly, causing increased hepatic necrotic tracts and
haemorrhaging resulting in acute and subacute fasciolosis.
The hepatic-stage histopathology is characterised by
acute necrotic foci and tracts, some of which are associ-
ated with haemorrhages. In the early stages of infection,
migrating NEJ are surrounded by relatively healthy hepatic
parenchyma, whereas necrotic tracts and haemorrhages
are found several millimetres behind the larvae, suggesting
that products shed or released by NEJ are responsible for
hepatic necrosis (Zafra et al., 2013a, 2013b). Migrating
larvae in sheep (Meeusen et al., 1995) and goats (Zafra
et al., 2013a, 2013b) are not surrounded by the inﬂam-
matory inﬁltrate, a feature which has been attributed
to the rapid migration of NEJ (Meeusen et al., 1995).
By contrast, in recent vaccine trials in goats, we found
that animals showing little hepatic damage exhibited
severe inﬁltration of eosinophils surrounding migratory
ﬂukes at early stages of infection (Zafra et al., 2013a,
2013b). Necrotic hepatic tissue induces chemotaxis of
inﬂammatory cells, particularly eosinophils, macrophages
and lymphocytes, which are found at the periphery of
necrotic areas. Macrophages become activated, increasing
in size and accumulate around the necrotic areas in a
palisade pattern, surrounded with lymphocytes to form
necrotising granulomas (Marcos et al., 2007; Zafra et al.,
2013a, 2013b). Small necrotic foci or tracts are phagocy-
tosed and removed by activated macrophages, but larger
necrotic areas are encapsulated by ﬁbrous connective
tissue, leading to tortuous ﬁbrous scars (chronic tracts)
after necrosis or haemorrhages are removed. Even in a
rinary P104 V. Molina-Hernández et al. / Vete
single dose infection, it is common to ﬁnd acute, subacute
and chronic tracts in the liver due to the same larvae
migrating for weeks, and thus the simultaneous migration
of many immature forms can cause severe damage to the
liver parenchyma. The clinical signs characterising this
stage of infection include jaundice, ill-thrift and anaemia
and can even result in death, particularly of young
animals.
The presence of adult ﬂukes within the bile ducts
induces a severe chronic cholangitis with erosion
and hyperplasia of the biliary epithelium, inﬁltrate of
eosinophils, lymphocytes and plasma cells in portal
areas, intraepithelial inﬁltration of globule leukocytes
and portal ﬁbrosis (Behm and Sangster, 1999; Perez et al.,
1999, 2002; Tliba et al., 2000; Zafra et al., 2008; Golbar
et al., 2013). These lesions, together with chronic tracts
induced during the migratory stage, are typical of chronic
fasciolosis (Perez et al., 2005; Zafra et al., 2008, 2013a,
2013b). Chronic fasciolosis is the most common form
in ruminants and occurs when the adults reach the bile
ducts. Clinically, it is characterised by similar signs as the
acute/subacute phase, together with persistent diarrhoea,
pallor of mucous membranes, weight loss, weakness, with
some animals developing oedema under the jaw (‘bottle
jaw’) (Behm and Sangster, 1999).
Adult ﬂukes feed on blood and hepatic parenchyma
adjacent to bile ducts, causing damage and focal rupture
of bile ducts, allowing some parasite eggs to reach the liver
parenchyma causing severe eosinophilic and granuloma-
tous inﬂammatory responses (Perez et al., 2002, 2005; Zafra
et al., 2008, 2013a, 2013b). At this stage, it has been shown
that in sheep, parasite excretory-secretory (ES) products
continue to stimulate a favourable immune environment
for parasite survival and induce apoptosis of inﬂamma-
tory cells in the pericholangiolar inﬂammatory inﬁltrates
(Escamilla et al., unpublished). The migratory behaviour of
the parasite may  be an immune evasion tactic as parasites
are rarely found in the tracts themselves but have moved
on leaving behind a trail of destruction. Lesions can also be
found in the liver where parasites are absent, suggesting
that antigens released by the parasite can become trapped
in the tissue and attract immune cell inﬁltration.
A major factor that contributes to hepatic damage is the
level of the infective dose. Previous studies revealed that,
after high infective doses, the lesions found were more
severe, even causing death of the animals during early
infection, whereas under low infective doses the disease
develops chronically (Behm and Sangster, 1999). Moreover,
studies carried out in sheep (Perez et al., 2002) and goats
(Martinez-Moreno et al., 1999; Perez et al., 1999) have
shown that small repeat infections, similar to those which
occur in natural infections (Clery et al., 1996), produce
more severe hepatic lesions than a single infective dose of
equal metacercariae number. These ﬁndings suggest that,
while the mechanical tissue-penetrating action of the par-
asite may  be the cause of hepatic damage, it is the ensuing
immune, or wound-healing, response that plays the major
role in the pathology of fasciolosis. The immunopatho-
logical cells comprise T lymphocytes (CD4+, CD8+ and
gamma-delta), B cells and macrophages, eosinophils and
mast cells which lead to the formation of large granulomasarasitology 208 (2015) 101–111
(Chauvin and Boulard, 1996; Martinez-Moreno et al., 1999;
Perez et al., 1999, 2002, 2005; Zafra et al., 2009).
Understanding how the immune system of various
ruminant hosts leads to tissue damage following primary
and subsequent infection with F. hepatica is still a huge
challenge to researchers but is essential to lay the basis
for effective vaccine development. Dissecting the myriad
of cytokines, chemokines and innate and adaptive cellular
pathways that are elicited to infection is critical to identify
those that are responsible for protecting against infection
whilst preventing excessive tissue damage. To date, we
know that F. hepatica infection drives the host immune
system towards an immunomodulatory response leading
to the activation of T helper (Th) 2 immune response
within 7 days of infection, with the concurrent produc-
tion of high titres of IgG1 antibodies without IgG2 (sheep
and cattle: Mulcahy et al., 1998, 1999; Walsh et al., 2009
and murine models: Donnelly et al., 2005, 2008), and a
down-regulation of Th1 immune response in murine mod-
els (Brady et al., 1999; O’Neill et al., 2000) and cattle (Flynn
et al., 2009). Thus, mouse studies indicate that while the
parasites induce host hepatic damage, it has the ability to
limit the extent of pro-inﬂammatory Th1-driven protec-
tive immune responses and promote anti-inﬂammatory
healing mechanisms, involving a Th2-mediated immune
response, M2  macrophages (Donnelly et al., 2005, 2008)
and mast cells (Vukman et al., 2013). Collectively, this pre-
vents the development of a protective immune response
against the parasite allowing the development of a chronic
infection. It is possible that, similar to infections with schis-
tosome parasites (Colley and Secor, 2014), the elaboration
of an anti-inﬂammatory/regulatory immune response is
important to protect the host from excessive immune-
mediated liver damage (McSorley and Maizels, 2012).
These anti-inﬂammatory immune responses may  be effec-
tive in preventing host mortalities in low-level infections,
but in high-level infections severe liver damage caused
by the migrating ﬂukes may overwhelm this protective
response and cause organ failure. This proposal is impor-
tant to consider for future vaccine development as their
efﬁcacy may  be highly dependent on infection dose, or
in a ﬁeld/herd situation a vaccine may  only be effective
in animals that acquire low-level infections. More studies
that investigate the effect of infection dose and repeated
infection on host immune responses are needed to under-
stand the impact of these schedules on liver tissue damage,
immune-related pathology and the overall pathogenesis of
liver ﬂuke infection.
5. There is no strong evidence of protective
immunity in ruminants to F. hepatica infection
Compounding the difﬁculty of F. hepatica vaccine
development is the lack of evidence for natural innate
and cellular immune-mediated resistance in ruminants
to these parasites (also reviewed by Piedraﬁta et al.,
2004). Few studies have directly addressed this question,
though Clery et al. (1996) have shown that cattle chron-
ically infected in the ﬁeld do not develop resistance to
an experimental challenge. Studies by Doy and Hughes
(1984) attempted to identify the tissue where resistance to
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nfection in cattle is mediated. While they found that cattle
nfected 18 or 26 weeks previously exhibited high levels of
esistance to a secondary challenge infection (56 and 94%,
espectively, assessed by ﬂuke number 15/16 weeks after
hallenge infection), no protection was observed if they
acriﬁced animals earlier, at 4–14 days after the challenge
nfection. From this data, they suggested that resistance
echanisms were effective against the challenge infection
fter the parasites penetrated the liver capsule. However,
hether these ‘protective mechanisms’ were immunolog-
cally mediated or result from tissue damage and ﬁbrosis
aused by the primary infection is open to debate. Indeed,
arly studies by Ross (1967), Boray (1967) and Doyle (1971)
uggested that protection in cattle to re-infection was
elated to tissue ﬁbrosis caused by the primary infection
hich retards the migration of the parasites in the chal-
enge infection; therefore, a high primary challenge leads to
reater liver ﬁbrosis and, consequently, seemingly greater
rotection compared to low primary infections. A more
ecent study by Hoyle and colleagues (2003) has indicated
hat infections with TCBZ-drug abbreviated F. hepatica
ould induce a partial protective response as judged by
easuring the serum levels of liver enzymes. However,
his study was not supported by estimations of parasite
urden and would need to be repeated to validate these
uggestions.
The only commercially available vaccine for any
uminant helminth is Huskvac. This consists of radiation-
ttenuated 3rd-stage larvae and is highly effective against
ungworm (husk) caused by the nematode, D. viviparus
McKeand, 2000). Likewise, radiation-attenuated larvae
cercariae) of Schistosoma mansoni induce high levels of
rotection (which is transferable with antibodies and
mmune cells) against a heterologous parasite challenge
nfection in mice and non-human primates and is the basis
f many approaches to vaccine development (Anderson
t al., 1999; Eberl et al., 2001; Bickle, 2009). Irradiation
f F. hepatica metacercariae can attenuate the parasites;
owever, while parasites successfully excyst and the NEJ
re capable of crossing the intestine and penetrating
he liver tissue, they do not develop beyond the equiv-
lent of 10-day-old normal parasites and, hence, they
ause little pathology (Boray, 1969; Rickard and Howell,
982; Hughes, 1987). Early studies by Dargie et al. (1974)
n cattle have shown that high dose infections with
adiation-attenuated parasites did not confer any resis-
ance to a challenge infection. In experiments in which
ome protection was observed following immune prim-
ng with radiation-attenuated metacarceriae, protection
as attributed to ﬂukes that escaped attenuation, devel-
ped normally and induced liver pathology and ﬁbrosis.
esults of these experiments would argue that the early
igratory stages of the parasite do not induce potent
mmunologically driven protective responses and that liver
athology/ﬁbrosis is predominantly responsible for protec-
ion against challenge.
As recently discussed by Toet et al. (2014), sheep appear
o offer no immunological resistance to infection with F.
epatica, and even Indonesian Thin Tailed (ITT) sheep that
licit a protective innate and adaptive response to Fasciola
igantica are susceptible to infection with F. hepatica.arasitology 208 (2015) 101–111 105
Furthermore, while peritoneal cells removed from F.
gigantica-infected ITT sheep (predominantly eosinophils
and macrophages) mediate antibody-dependent cytotox-
icity against F. gigantica NEJ in vitro by the production
of superoxide radicals, this mechanism was ineffective
against F. hepatica NEJ (Piedraﬁta et al., 2007). These stud-
ies suggest that F. hepatica NEJ possess a unique ability to
resist killing by reactive oxygen species released by sheep
innate immune effector cells, which may  involve the high
expression of antioxidant enzymes such as superoxide dis-
mutase, glutathione S transferase (GST) or peroxiredoxin
(Piedraﬁta et al., 2000, 2007; Donnelly et al., 2005, 2008).
Sheep do not develop such a marked ﬁbrotic reaction
in the liver parenchyma or calciﬁcation of the bile ducts
compared to cattle infected with F. hepatica (reviewed by
Behm and Sangster, 1999) leaving them highly susceptible
to disease which can be fatal at high doses. From a vaccine
perspective, the differences between cattle and sheep
immune responses are important to delineate. In particu-
lar, while the targets at which the vaccine may  be directed
could be the same for cattle and sheep, the formulation,
delivery regime and administration methods may  need to
be tailored to elicit efﬁcacious immune responses in each
species.
We propose that infection of ruminants with F. hepatica
induces potent immune suppression or modulation to an
extent that animals are susceptible to further infection with
liver ﬂukes (and other pathogens). The developing Th2-
driven immune response, and suppressed Th1 response,
that lead ultimately to an immune regulatory environ-
ment, may  be necessary to secure parasite survival and at
the same time prevent excessive immune-mediated dam-
age to the liver (particularly by containing the damage
within the parasite tracts, and laying down ﬁbrotic tissue).
However, this immune response may  not be sufﬁcient to
prevent death resulting from organ failure caused by high-
level or repeated infections. It follows that future vaccine
programmes need to target parasite molecules that are
involved in early stage migration, tissue penetration and
immune evasion/suppression.
6. Vaccine candidates
The recent review by Toet et al. (2014) has summarised
our progress in vaccine development against F. hepatica,
and the related parasite F. gigantica, over the last three
decades. Interestingly, most of the vaccine candidates were
ﬁrst isolated as native proteins, usually from adult worm
ES products, because this antigen preparation was  not very
complex and was  easy to obtain. Several of these early
antigens, including cathepsin L proteases, GST and fatty
acid binding protein (FABP) induced signiﬁcant protection
in cattle and sheep (reviewed by Toet et al., 2014), reducing
not only worm burden (and egg output), but also liver
pathology. Recent reports of vaccine trials in sheep with
several recombinant but functional forms of these antigens
such as cathepsin L1 (CL1), GST and peroxiredoxin (FhPrx)
from F. hepatica, or Sm14 peptide from S. mansoni, have not
reported signiﬁcant reduction of worm burdens but have
shown reduced liver pathology (Piacenza et al., 1999; Zafra
et al., 2009, 2013a, 2013b; Mendes et al., 2010; Perez-Ecija
rinary P106 V. Molina-Hernández et al. / Vete
et al., 2010; LaCourse et al., 2012; Toet et al., 2014). While
enthusiasm for bringing these antigens forward as future
vaccines has waned largely because of inconsistency of vac-
cine results (such as with GST and cathepsin L, see Spithill
et al., 1999b; Toet et al., 2014), in our opinion, there has not
be an exhaustive assessment of these antigens in terms of
formulation and delivery (as well as combination vaccines)
and, hence, we would disagree with Toet et al. (2014) in
dismissing molecules such as GST and FABP as potential
future vaccines because of the discrepancy between avail-
able data. Furthermore, recent genomics/transcriptomic
data reveal these proteins belong to large families with
complex developmental expression patterns (Cwiklinski
et al., unpublished) that need to be explored further to
ensure that the appropriate member(s) are those that
are brought into vaccines trials. The observation that
adult worm-derived antigens can induce protection at
the level of the liver (and possibly earlier) would suggest
that these antigens are either also expressed by the
juvenile/immature parasite stages or that the immune
response cross-reacts between the various members of
the same family. If the latter scenario is the case, then
perhaps focusing on family members that are expressed
by the early stage parasites would prove more promising.
Encouraging results from schistosome vaccine trials
has shown that utilising combinations of antigens can
increase the efﬁcacy of vaccines (Nascimento et al., 2002).
Nascimento et al. (2002) showed that using a triple anti-
gen vaccine with a combination of Sm14, IrV5 and ECL
antigens, showed the highest level of protection when com-
pared with single antigens alone. Similar studies have also
recently been carried out using a multi-antigen approach
for the nematode parasites, H. contortus (Smith et al., 2001;
LeJambre et al., 2008) and T. circumcincta (Nisbet et al.,
2013) with promising results suggesting that a vaccine
combination approach may  be the only way to combat
these complex parasites, including F. hepatica.
7. Cathepsins L and B proteases: important to the
parasite and prime vaccine targets
F. hepatica relies on proteolytic activity for many of
its pivotal functional activities in the host, including tis-
sue penetration, migration, feeding and immune evasion
and, hence, it is not surprising that these have been the
most encouraging candidates for vaccine development for
some time (Dalton et al., 2013). Adult parasites secrete
an abundance of cathepsin L cysteine proteases, repre-
senting about 80% of the total protein from adult ES,
that they use for digesting the protein contents of the
blood, including haemoglobin, albumin and immunoglobu-
lin, consistent with ES protein analysis (Wilson et al., 2011).
This provides free amino acids required for synthesising
egg proteins (Robinson et al., 2008a). Native cathepsin L
proteases are readily isolated from adult ES products by
standard gel permeation and ion exchange chromatog-
raphy into two ‘homogeneous’ fractions (termed FhCL1
and FhCL2) (Smith et al., 1993; Dowd et al., 1994). The
highly signiﬁcant protection (regularly 50–55% reduction
in worm burden and egg production) observed using these
native preparations when delivered in Freund’s completearasitology 208 (2015) 101–111
adjuvant was further enhanced (72.4%) when combinations
were made with proteins contained in a high molecu-
lar weight haem-containing (Hb) fraction. The Hb fraction
itself induced low but signiﬁcant protection (43.8%) in
cattle against a challenge infection and recent proteomic
analysis has revealed that this mixture includes peroxire-
doxin (FhPrx), the helminth defense molecule (FhHDM)
and fatty acid binding protein (FABP), all of which can
induce modulation of host immune responses including
alterations in macrophage function (Robinson et al., 2011b,
2012; Thivierge et al., 2013; Dalton et al., 2013; Figueroa-
Santiago and Espino, 2014). In sheep, a combination of the
FhCL1 and FhCL2 induced 60% protection but were less efﬁ-
cacious when used individually (34 and 33%, respectively).
Surprisingly, neither FhCL1 nor FhCL2 enhanced the efﬁ-
cacy of F. hepatica leucine aminopeptidase, which alone
was  highly efﬁcacious (89%) in sheep (Piacenza et al., 1999).
Our understanding of F. hepatica proteases, and other
secreted proteins, has been greatly improved by the avail-
ability of proteome data (Jefferies et al., 2001; Morphew
et al., 2007; Robinson et al., 2008b, 2009) and by integrat-
ing this with an analysis of the transcriptome (Robinson
et al., 2009). We now know that FhCL1 and FhCL2 are
not expressed and secreted by the NEJ as they penetrate
the liver and intestine; these early-stage parasites pro-
duce different members of the cathepsin L family, FhCL3
and FhCL4. FhCL3 is particularly abundant and secreted
by NEJ while FhCL4 may  play a more housekeeping role
(Cancela et al., 2008; Robinson et al., 2008b, 2009). The
expression of FhCL3 is down-regulated soon after the par-
asite enters the liver parenchyma while FhCL1, FhCL2 and
another family member, FhCL5, become more predomi-
nant as the parasite migrates and prepares to enter the
bile ducts. These changes in protease expression reﬂect
the parasite’s adaptation to its changing environment as
it migrates through different tissues and encounters new
macromolecules. Molecular and biochemical analysis of
FhCL3 (Corvo et al., 2009, 2013; Robinson et al., 2011a)
have shown that this enzyme possesses a constellation of
residues in its active site that confer it with a unique ability
to digest collagen, suggesting that this protease is critical
to parasite penetration of the intestine and liver capsule
(Dalton et al., 2006). Once within the liver parenchyma
FhCL2, which also exhibits collagenolytic activity (albeit,
not are effective as FhCL3), together with FhCL1 and FhCL5,
which both lack collagenolytic activity (Robinson et al.,
2011a), combine to generate an efﬁcient tissue-degrading
and feeding mechanism. Once in the bile ducts, the para-
sites rely most heavily on FhCL1 which has an active site
arrangement that gives this protease a marked preference
for cleaving peptide bonds involving residues (Leu, Ala and
Phe) that are common in haemoglobin and, hence, appears
to be speciﬁcally adapted to blood feeding (Lowther et al.,
2009).
Interestingly, a similar highly regulated pattern of
expression occurs with the cathepsin B proteases. Several
cathepsin B proteases (FhCB1, FhCB2 and FhCB3) show par-
allel expression with the FhCL3, i.e. are secreted by the early
NEJ but are down-regulated as the parasite migrates in the
liver tissue. This would suggest that the concerted action
of FhCL3/FhCBs is essential for successful intestine and
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iver penetration. In support of this suggestion, McGonigle
t al. (2008) demonstrated that RNAi-mediated knockdown
f either the NEJ FhCLs or FhCBs blocked their ability to
raverse the intestine wall. Once in the liver, the para-
ite cathepsin B proteases (FhCB1, FhCB2 and FhCB3) are
witched off but, in contrast to the cathepsin Ls, are not
eplaced by other family members (other members exist
ut present studies indicate that these are not secreted and
ay  play a role in the internal tissues/cells of the parasite).
t appears that the role of liver migration, tissue feeding
nd then blood digestion while residing in the bile ducts is
he sole responsibility of the FhCL1, FhCL2 and FhCL5.
The exquisite control of the expression of the cysteine
roteases as the parasites migrates and establishes a long-
ived infection in the host is now guiding our strategy for
accine development. Given that partial protection against
nfection can be achieved in ruminants by vaccination with
 single recombinant protease such as FhCL1, which is pre-
ominantly secreted in the bile duct, it may  be judicious for
heep and cattle vaccines to combine this with other fam-
ly members, most particularly FhCL3, or with members of
he cathepsin B family (FhCB1, 2 or 3), that are more specif-
cally expressed in the early juvenile stages. Experiments in
ats achieved a level of 83% protection by combining FhCB2
ith FhCL5 (Jayaraj et al., 2009).
. Future direction using next-generation
echnologies
Following the development and advancement of next-
eneration sequencing technologies, large sequence data
ets are now being generated for several parasites (Huang
t al., 2013; Gobert et al., 2014; Young et al., 2014;
orrester and Hall, 2014). Genome data sets can inform
unctional genomics analysis, including transcriptomics,
roteomics, secretomics and epigenomics. Utilising all
vailable ‘omics’ data for a particular parasite provides
n unbiased approach to understanding parasite biology,
ather than focusing on a particular gene or protein. Fur-
hermore, we can now perform in-depth analysis of the
tructure and expression of complex gene families. This
ill provide a comprehensive understanding of which
enes/proteins are important at each stage of develop-
ent, especially those acting at the host–parasite interface,
hich are of potential importance for invasion and infec-
ion. Furthermore, we are now beginning to probe the
nterfaces between the host and parasite and monitor
heir dynamics. Accordingly, those molecules released by
he parasite into the host tissues either as soluble mix-
ures (Robinson et al., 2008b, 2009) or part of the cargo
f vesicles/microparticles (Marcilla et al., 2012) have been
eported. A detailed characterisation of the ﬂuke surface
egument has also been carried out (Wilson et al., 2011;
oet et al., 2014) which may  also be exploited as vaccine
nd diagnostic targets (Prasanphanich et al., 2013). Reverse
enetics tools such as RNAi can be used for F. hepatica and
urrently represents a most direct means to investigate
he functionality of NEJ proteins (McGonigle et al., 2008;
inaldi et al., 2008; McVeigh et al., 2014).
Recently, a draft F. hepatica genome has been completed
ogether with extensive transcriptome datasets for severalarasitology 208 (2015) 101–111 107
lifecycle stages, NEJ (1-, 3- and 24-h post-excystment),
21–day-old juveniles and mature adult ﬂukes (Cwiklinski
et al., unpublished). Using clustering analysis, genes
exhibiting similar temporal expression patterns have
been grouped to provide a more complete picture of
which genes are important at each stage of development,
which will allow us to investigate how the functions are
inter-connected. For example, when this analysis was
applied to cathepsin L and cathepsin B genes, it supported
our previous ﬁndings regarding their strict developmental
regulation as described above, as well as providing a
more detailed and reliable clariﬁcation of the gene family
members. Exploiting this cluster analysis will allow the
development of a framework from which a multi-antigen
vaccine programme targeted towards a speciﬁc lifecycle
stage or several stages can be implemented.
The extensive sequencing carried out for several F.
hepatica isolates has also revealed that these helminths
are highly polymorphic and, therefore, likely to be highly
adaptable (Cwiklinski et al., unpublished). In particular, the
high level of genetic diversity could explain the emergence
of anthelmintic resistance in diverse F. hepatica populations
across the world and should inﬂuence future control strate-
gies, using drugs and/or vaccines. Anthelmintic resistance
is likely to be multi-genic, and possibly involving differ-
ent genes each time resistance evolves in different ﬂuke
populations across the world, which poses several ques-
tions regarding how data from different ﬂuke populations
can be interpreted. Will different parasite populations,
even within similar geographical locations, respond differ-
ently to new drug and vaccine control strategies? Is the
inconsistency observed in vaccine trials (inter- and intra-
laboratory) due to the use of different ﬂuke populations or
genetic variation within populations? Potential variations
between ﬂuke populations need to be considered for any
control strategy and, more relevantly, suggest that a multi-
antigenic approach to vaccine development may  have a
better chance of succeeding.
9. Conclusion
Over the last few decades, much progress has been made
in the isolation, characterisation and testing of a number
of native and recombinant molecules as vaccines against
liver ﬂuke disease in ruminant hosts (Toet et al., 2014).
Despite signiﬁcant success, however, data between trials,
even within the same laboratories, have shown a large
degree of inconsistency. Much of this could be attributed
to variations in a number of elements within the protocols
employed, including vaccine schedules and formulations,
age of animals, breed of animals, number of animals within
groups, infection doses and infections regimes. Indeed, it
is important that as we  move forward within the research
ﬁeld, a standardised vaccine protocol is established to allow
comparison of results between trials. For the same rea-
son, as new immunological reagents become available to
improve our analysis of ruminant immune responses, it
is critical that we develop standard operation procedures
(SOPs) for both sheep and cattle, and other species.
Fasciolosis is a hepatobiliary disease and, therefore, dys-
function of liver is the predominant physio-pathological
rinary P108 V. Molina-Hernández et al. / Vete
complication that affects the total health status of the
animal. This damage is caused directly by the para-
site’s migratory activity and indirectly by the host’s
immune response to parasite-secreted molecules and tis-
sue damage. Therefore, reduction of the magnitude of the
pathological damage by vaccinations may  be as signiﬁcant
as reducing worm burden. While ﬂuke burden and liver
damage are likely to be interrelated, judging vaccine efﬁ-
cacy solely by enumerating ﬂuke burden may  not provide
an overall accurate assessment of the beneﬁt of a vaccine.
Many vaccine trial protocols involve sacriﬁcing animals at
the chronic stage of infection when the challenge para-
sites are in the bile ducts and easily recovered. However, at
this time point, liver damage cannot be easily graded as it
contains both acute- and chronic-associated damage. Per-
haps, we should consider placing a greater importance on
diagnostic methods of hepatic pathology, so that protection
against liver disease at early stages of infection can be quan-
tiﬁed: such as estimating liver enzymes in serum (aspartate
transaminase: AST, alkaline phosphatase: ALP, gamma-
glutamyl transferase: GGT and glutamate dehydrogenase:
GLDH) or ﬁnding novel serum biomarkers, such as the study
by Rioux et al. (2008) that indicates several serological
markers could be used for assessing liver damage.
The pursuit of a F. hepatica vaccine needs to focus
on understanding ﬂuke biology, speciﬁcally the proteins
involved in the tissue invasion and migration within the
deﬁnitive host. It is our opinion that the most effective
vaccine would be one that is directed against the early
migratory stages of the parasite, including surface tegu-
mental proteins/glycoproteins and secreted molecules,
with the primary aim of preventing the penetration of
the liver capsule by the parasites. However, other vac-
cine strategies may  include targeting those molecules
that suppress the development of Th1-mediated immune
responses, those antigens that induce liver damage and/or
attract the inﬁltration of immune cells or, indeed, the sen-
sory molecules that facilitate the migration of the ﬂuke
from intestine to liver to bile duct. This presents us with
the challenge of learning more about the early migra-
tory stages of F. hepatica, a stage that has traditionally
been neglected, particularly in ruminants, due to the dif-
ﬁculty of obtaining workable levels of parasite material.
However, genomic, transcriptomic and proteomic methods
have made the molecular dissection of this parasite stage
possible and will facilitate the rational design of single and
multiple antigen vaccine cocktails. It is imperative that we
bolster this molecular progress with new methodologies
and by combining robust immunological analysis of innate
and adaptive responses with pathological analysis of the
early stages of infection to understanding how and when
the parasite initiates control of host immune responses.
Finally, translating experimental ﬁndings to the ﬁeld
will throw up many challenges including issues related
to parasite polymorphism as described above. Also,
developing effective vaccine formulations that will induce
potent protection in the ﬁeld with low antigen dose and
the minimum number of injections (preferably two or
less) will be required to make these commercially viable.
Nevertheless, ﬁeld trials will provide valuable information
of vaccine performance (e.g., potency and longevity) atarasitology 208 (2015) 101–111
a ‘herd’ level where infection rates can vary signiﬁcantly
between animals and will help answer the critical question
of whether vaccinating is more beneﬁcial or ﬁnancially
worthwhile than not vaccinating to the end-user, i.e.
farmers. Clearly, we are not there yet but the road ahead
looks very promising.
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